MiAlgae is accelerating its mission to produce omega-3s and is its leadership team with the appointment of Jerome Quiohilag as associate director.
The company repurposes whisky industry byproducts to grow microalgae as a sustainable, cost-effective alternative to fish-derived omega-3 sources. After being named a finalist in the Earthshot Prize last year, MiAlgae continues to scale operations and expand its global impact.
Jerome Quiohilag joins MiAlgae from Veranova, a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients (APIs) for pharma and biotech customers. At Veranova, he was responsible for overseeing the production of medicinal products, ensuring compliance with strict quality and safety standards.
With more than a decade of experience in pharmaceutical manufacturing, he has successfully led high-performing teams across diverse manufacturing environments, directing operations to meet strategic business objectives while driving efficiency and process optimization.
In his new role, Jerome will play a key role in scaling MiAlgae’s production capacity, enhancing manufacturing efficiency, and supporting the company’s ambitious growth plans.
Last year, MiAlgae successfully reached commercial-scale production of NaturAlgae, its sustainable marine omega-3 product, at its Scottish demonstrator site. Now, the company is preparing for its next major milestone – the development of an industrial-scale production facility in Scotland, with the first phase set for completion in 2025.
At this pivotal stage of expansion, Jerome is excited to contribute to MiAlgae’s mission. “This is a unique opportunity to join a fast-growing company with a clear mission and global ambition. I look forward to applying my expertise to scale operations and contribute to a greener, more sustainable future.”
Douglas Martin, founder and managing director of MiAlgae, added, “We’re thrilled to welcome Jerome at this exciting time for MiAlgae. His expertise will be crucial as we scale up to meet growing demand and continue driving biotech innovation.”
